Paper Details

  1. Home
  2. Paper Details

Emerging drugs for treatment of anemia of chronic kidney disease.

Author: BennettCharles L, ChenBrian, KesslerSam, LebbyAkida, MagwoodJametta S, NorrisLeAnn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Erythropoiesis-stimulating agents (ESAs) are essential for preventing transfusions in anemic patients with chronic kidney disease (CKD). However, traditional ESAs, erythropoietin (EPO), and darbepoietin are associated with increased risks of thromboembolism and myocardial events. New, less frequent but equally effective ESAs are needed to improve patient well-being and quality of life.
Paper Details　
Original Abstract of the Article :
Erythropoiesis-stimulating agents (ESAs) prevent transfusions among anemic patients with chronic kidney disease (CKD). Clinical trials, meta-analyses, and guidelines identify arterial and venous thromboembolism as well as myocardial event risks with the traditional ESAs, erythropoietin (EPO), and da...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14728214.2013.836490

データ提供：米国国立医学図書館（NLM）

Anemia in CKD: Navigating the Desert of Treatment Options

The management of [anemia of chronic kidney disease] presents a significant challenge in the field of [renal medicine]. While [erythropoiesis-stimulating agents (ESAs)] have traditionally been used to prevent [transfusions] in anemic patients with [CKD], their use is not without risks. This article reviews the current landscape of [ESA] therapy, highlighting the need for [less frequent but equally effective ESAs] to improve patient well-being and quality of life.

Balancing the Scales of Anemia Treatment

This article delves into the complex world of [ESA] therapy for [anemia of chronic kidney disease]. While [ESAs] have proven effective in preventing [transfusions], they can also lead to [arterial and venous thromboembolism] as well as [myocardial event risks]. This emphasizes the need for careful monitoring and individualized treatment approaches to minimize these risks and improve patient outcomes.

Navigating the Desert of Anemia Management

Managing [anemia of chronic kidney disease] is akin to traversing a vast desert landscape, filled with challenges and potential pitfalls. This article sheds light on the current limitations of [ESA] therapy and highlights the need for alternative treatment options that are more effective and better tolerated. This research paves the way for a more personalized and effective approach to managing [anemia of chronic kidney disease], ultimately leading to better patient outcomes and improved quality of life.

Dr.Camel's Conclusion

This review highlights the ongoing challenges in managing [anemia of chronic kidney disease] and the need for new and improved treatment options. While [ESAs] have been a valuable tool in preventing [transfusions], their associated risks necessitate the development of more effective and safer therapies. This research emphasizes the importance of continuous innovation in [renal medicine] to improve the lives of patients living with [CKD].

Date :
  1. Date Completed 2014-07-14
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

24033253

DOI: Digital Object Identifier

10.1517/14728214.2013.836490

Related Literature

Article Analysis
・Side Effects of epoetin alfa
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.